# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
- New clinical, PK and PD data from novel CDK2/9 inhibitor fadraciclib monotherapy studies support ongoing development program ...
Cyclacel Pharmaceuticals (NASDAQ:CYCC) reported quarterly losses of $(6.23) per share which missed the analyst consensus estima...
Companies Reporting Before The Bell • Tencent Music Enter Gr (NYSE:TME) is projected to report quarterly earnings at $0.14 per...